5,361 Shares in AstraZeneca PLC (NASDAQ:AZN) Acquired by Bank of Nova Scotia

Bank of Nova Scotia acquired a new position in shares of AstraZeneca PLC (NASDAQ:AZNGet Rating) in the second quarter, according to the company in its most recent disclosure with the SEC. The firm acquired 5,361 shares of the company’s stock, valued at approximately $355,000.

A number of other hedge funds have also recently made changes to their positions in AZN. Arrowstreet Capital Limited Partnership boosted its position in shares of AstraZeneca by 407.1% during the 1st quarter. Arrowstreet Capital Limited Partnership now owns 4,093,345 shares of the company’s stock worth $271,553,000 after purchasing an additional 3,286,137 shares during the period. 1832 Asset Management L.P. boosted its position in AstraZeneca by 239.6% in the 1st quarter. 1832 Asset Management L.P. now owns 3,033,929 shares of the company’s stock valued at $198,533,000 after buying an additional 2,140,670 shares during the period. Farallon Capital Management LLC boosted its position in AstraZeneca by 87.6% in the 1st quarter. Farallon Capital Management LLC now owns 3,576,184 shares of the company’s stock valued at $237,244,000 after buying an additional 1,670,029 shares during the period. Capital International Investors boosted its position in AstraZeneca by 4.5% in the 1st quarter. Capital International Investors now owns 36,993,664 shares of the company’s stock valued at $2,458,428,000 after buying an additional 1,604,875 shares during the period. Finally, Ensign Peak Advisors Inc boosted its position in AstraZeneca by 179.9% in the 1st quarter. Ensign Peak Advisors Inc now owns 2,398,337 shares of the company’s stock valued at $159,106,000 after buying an additional 1,541,513 shares during the period. Hedge funds and other institutional investors own 21.55% of the company’s stock.

AstraZeneca Price Performance

Shares of NASDAQ:AZN opened at $65.07 on Monday. The company has a debt-to-equity ratio of 0.65, a current ratio of 0.81 and a quick ratio of 0.67. The firm has a market capitalization of $201.64 billion, a P/E ratio of 97.12, a P/E/G ratio of 1.32 and a beta of 0.50. AstraZeneca PLC has a 12 month low of $52.65 and a 12 month high of $71.70. The company’s fifty day moving average price is $57.76 and its 200 day moving average price is $62.02.

Analyst Ratings Changes

Several equities analysts have commented on AZN shares. AlphaValue raised shares of AstraZeneca to a “reduce” rating in a research report on Monday, August 22nd. Argus raised shares of AstraZeneca from a “hold” rating to a “buy” rating in a research report on Monday, August 29th. StockNews.com started coverage on shares of AstraZeneca in a research report on Wednesday, October 12th. They set a “buy” rating for the company. Berenberg Bank decreased their price objective on shares of AstraZeneca from GBX 120 ($1.41) to GBX 118 ($1.39) in a research report on Wednesday, October 19th. Finally, Credit Suisse Group cut shares of AstraZeneca from an “outperform” rating to a “neutral” rating in a research report on Thursday, September 15th. One research analyst has rated the stock with a sell rating, six have assigned a hold rating and six have assigned a buy rating to the company’s stock. According to MarketBeat.com, the company presently has an average rating of “Hold” and an average target price of $8,264.20.

AstraZeneca Company Profile

(Get Rating)

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacturing, and commercialization of prescription medicines. Its marketed products include Calquence, Enhertu, Faslodex, Imfinzi, Iressa, Koselugo, Lumoxiti, Lynparza, Orpathys, Tagrisso, and Zoladex for oncology; Brilinta/Brilique, Bydureon/Byetta, BCise, Byetta, Crestor, Evrenzo, Farxiga/Forxiga, Komboglyze/Kombiglyze XR, Lokelma, Onglyza, Qtern, and Xigduo/Xigduo XR for cardiovascular, renal, and metabolism diseases; Bevespi Aerosphere, Breztri Aerosphere, Daliresp/Daxas, Duaklir Genuair, Fasenra, Pulmicort, Saphnelo, Symbicort, and Tudorza/Eklira/Bretaris for respiratory and immunology; and Andexxa/Ondexxya, Kanuma, Soliris, Strensiq, and Ultomiris for rare diseases.

See Also

Want to see what other hedge funds are holding AZN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for AstraZeneca PLC (NASDAQ:AZNGet Rating).

Institutional Ownership by Quarter for AstraZeneca (NASDAQ:AZN)

Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with MarketBeat.com's FREE daily email newsletter.